These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36016287)

  • 21. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
    Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
    Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
    Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
    J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of SARS-CoV-2 nucleic acid amplification testing in Austria as measured by external quality assessment schemes during 3 years of the COVID-19 pandemic: an observational retrospective study.
    Buchta C; Aberle SW; Allerberger F; Benka B; Görzer I; Griesmacher A; Hübl W; Huf W; Kapiotis S; Müller MM; Neuwirth E; Puchhammer-Stöckl E; Weseslindtner L; Camp JV
    Lancet Microbe; 2023 Dec; 4(12):e1015-e1023. PubMed ID: 37979591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
    Hayer J; Urlaub E
    Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays.
    Poore B; Nerenz RD; Brodis D; Brown CI; Cervinski MA; Hubbard JA
    Clin Biochem; 2021 Sep; 95():77-80. PubMed ID: 34118242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical diagnostic performance evaluation of five immunoassays for antibodies to SARS-CoV-2 diagnosis in a real-life routine care setting.
    Akyala AI; Awayimbo JR; Ogo AC; Chima NJ; Billyrose OMA; Engom AOG
    Pan Afr Med J; 2021; 39():3. PubMed ID: 34178231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage.
    Buchta C; Springer D; Jovanovic J; Borsodi C; Weidner L; Sareban N; Radler U; Müller MM; Griesmacher A; Puchhammer-Stöckl E; Wagner T; Jungbauer C; Stiasny K; Weseslindtner L
    Clin Chem Lab Med; 2023 Jun; 61(7):1349-1358. PubMed ID: 36756735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19.
    Chiereghin A; Zagari RM; Galli S; Moroni A; Gabrielli L; Venturoli S; Bon I; Rossini G; Saracino IM; Pavoni M; Lafratta S; Deni A; Felici S; Borghi M; Guerra L; Raumer L; Lodi V; Viale P; Attard L; Lazzarotto T;
    Front Public Health; 2020; 8():620222. PubMed ID: 33681115
    [No Abstract]   [Full Text] [Related]  

  • 31. Interlaboratory Agreement of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serologic Assays in the Expedited College of American Pathologists Proficiency Testing Program.
    Tacker DH; Bashleben C; Long TC; Theel ES; Knight V; Kadkhoda K; Rhoads DD; Linden MA; Fink SL
    Arch Pathol Lab Med; 2021 May; 145(5):536-542. PubMed ID: 33461214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay.
    Kittel M; Findeisen P; Muth MC; Thiaucourt M; Gerhards C; Neumaier M; Haselmann V
    Int J Infect Dis; 2021 Apr; 105():632-638. PubMed ID: 33578017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance evaluation of SARS-CoV-2 antigen detection in the post-pandemic era: multi-laboratory assessment.
    Chen Y; Feng L; Han Y; Zhao Z; Diao Z; Huang T; Ma Y; Feng W; Li J; Li Z; Liu C; Chang L; Li J; Zhang R
    Clin Chem Lab Med; 2023 Nov; 61(12):2237-2247. PubMed ID: 37377068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical characterization of the SARS-CoV-2 EURM-017 reference material.
    Freeman J; Olson K; Conklin J; Shalhoub V; Johnson BA; Bopp NE; Fernandez D; Menachery VD; Aguilar PV
    Clin Biochem; 2022 Mar; 101():19-25. PubMed ID: 34933006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG.
    Gambino CM; Lo Sasso B; Colomba C; Giglio RV; Agnello L; Bivona G; Ciaccio M
    Biochem Med (Zagreb); 2020 Oct; 30(3):030901. PubMed ID: 33071558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the National External Quality Assessment for Toxoplasmosis Serological Testing in China.
    Zhang K; Wang L; Lin G; Sun Y; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(6):e0130003. PubMed ID: 26066047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation.
    Jääskeläinen AJ; Kuivanen S; Kekäläinen E; Ahava MJ; Loginov R; Kallio-Kokko H; Vapalahti O; Jarva H; Kurkela S; Lappalainen M
    J Clin Virol; 2020 Aug; 129():104512. PubMed ID: 32563180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of six SARS-CoV-2 serology assays: Diagnostic performance and antibody dynamics in a cohort of hospitalized patients for moderate to critical COVID-19.
    Chamkhi S; Dhaouadi T; Sfar I; Mokni S; Jebri A; Mansouri D; Ghedira S; Ben Jemia E; Ben Boujemaa S; Houissa M; Aouina H; Ben Abdallah T; Gorgi Y
    Int J Immunopathol Pharmacol; 2022; 36():20587384211073232. PubMed ID: 35113728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.